Shanghai Yizhong (688091.SH): Injectable paclitaxel polymer micelles approved for clinical trials

Zhitongcaijing · 10/15 07:49

Zhitong Finance App News, Shanghai Yizhong (688091.SH) issued an announcement. The company recently learned from the China Drug Administration website that the company's core product, paclitaxel polymer micelles for injection, have obtained the “Drug Clinical Trial Approval Notice” and agreed to carry out clinical trials with new indications for pancreatic cancer. A multicenter, randomized, open, parallel group, positive drug-controlled phase III clinical trial evaluating the efficacy and safety of injectable paclitaxel polymer micelles combined with gemcitabine and injectable paclitaxel (albumin binding type) combined with gemcitabine in first-line treatment of metastatic pancreatic cancer.

This test is an effective design test of injectable paclitaxel polymer micelles combined with gemcitabine compared with albumin paclitaxel combined with gemcitabine. The purpose of the test was to compare and evaluate clinical research indicators such as progression-free survival (PFS), overall survival (OS), objective response rate (ORR), and disease control rate (DCR) of the two groups of patients.